The Effects of beta-hydroxy-beta-methylbutyrate supplementation in decompensated cirrhosis patients with sarcopenia: Randomize controlled trial, Preliminary Study

Start Date25 Apr 2023

Sponsor / Collaborator

Khon Kaen University

RBR-9snttn

/ Not yet recruitingPhase 4

Effect of Leucine and Beta-hydroxy-beta-methyl-butyrate supplementation on nutritional status, lean mass, functionality, biochemical and molecular markers of patients on the waiting list for liver transplantation

Start Date01 Jul 2020

Sponsor / Collaborator

Universidade Federal de Minas Gerais

[+1]

ChiCTR2000028778

/ RecruitingNot ApplicableIIT

The application of SARC-F scale in screening of Sarcopenia in Chinese elderly and the evaluation of intervention effect of beta-hydroxy-beta-methyl butyrate

Start Date31 Dec 2019

Sponsor / Collaborator-

100 Clinical Results associated with Beta-Hydroxy-Beta-Methylbutyrate

100 Translational Medicine associated with Beta-Hydroxy-Beta-Methylbutyrate

100 Patents (Medical) associated with Beta-Hydroxy-Beta-Methylbutyrate

Literatures (Medical) associated with Beta-Hydroxy-Beta-Methylbutyrate

31 Dec 2025·Journal of the International Society of Sports Nutrition

International society of sports nutrition position stand: β-hydroxy-β-methylbutyrate (HMB)

Review

Author: Harty, Patrick S. ; Rathmacher, John A. ; Townsend, Jeremy R. ; Kreider, Richard B. ; Antonio, Jose ; Candow, Darren G. ; Stout, Jeffrey R. ; Arent, Shawn M. ; Kalman, Douglas S. ; Kerksick, Chad M. ; Pitchford, Lisa M. ; Jäger, Ralf ; Campbell, Bill I. ; Roberts, Brandon M.

Position Statement: The International Society of Sports Nutrition (ISSN) bases the following position stand on an analysis of the literature regarding the effects of β-Hydroxy-β-Methylbutyrate (HMB). The following 12 points have been approved by the Research Committee of the Society: 1. HMB is a metabolite of the amino acid leucine that is naturally produced in both humans and other animals. Two forms of HMB have been studied: Calcium HMB (HMB-Ca) and a free acid form of HMB (HMB-FA). HMB-FA appears to lead to increased appearance of HMB in the bloodstream when compared to HMB-Ca, though recent results are mixed. 2. The available safety/toxicity data suggest that chronic HMB-Ca and HMB-FA consumption are safe for oral HMB supplementation in humans up to at least one year. 3. There are no negative effects of HMB-Ca and HMB-FA on glucose tolerance and insulin sensitivity in humans. There may be improvements in glucose metabolism in younger adults. 4. The primary mode of action of HMB appears to be through its dual mechanism to enhance muscle protein synthesis and suppress muscle protein breakdown. HMB's activation of mTORC1 is independent of the leucine-sensing pathway (Sestrin2-GATOR2 complex). 5. HMB may help reduce muscle damage and promote muscle recovery, which can promote muscle growth/repair. HMB may also have anti-inflammatory effects, which could contribute to reducing muscle damage and soreness. 6. HMB consumption in close proximity to an exercise bout may be beneficial to increase muscle protein synthesis and attenuate the inflammatory response. HMB can provide a beneficial physiological effect when consumed both acutely and chronically in humans. 7. Daily HMB supplementation (38 mg/kg body weight) in combination with exercise training may improve body composition through increasing lean mass and/or decreasing fat mass with benefits in participants across age, sex, and training status. The most pronounced of these improvements in body composition with HMB have been observed in studies with robust resistance training programs and dietary control. 8. HMB may improve strength and power in untrained individuals, but its performance benefits in trained athletes are mixed and increase with an increase in study duration (>6 weeks). HMB's beneficial effects on athletic performance are thought to be driven by improved recovery. 9. HMB supplementation appears to potentially have a positive impact on aerobic performance, especially in trained athletes. The mechanisms of the effects are unknown. 10. HMB supplementation may be important in a non-exercising sedentary and aging population to improve muscle strength, functionality, and muscle quality. The effects of HMB supplementation with exercise are varied, but the combination may have a beneficial effect on the treatment of age-associated sarcopenia under select conditions. 11. HMB may be effective in countering muscle disuse atrophy during periods of inactivity due to illness or injury. The modulation of mitochondrial dynamics and lipid metabolism by HMB may be a potential mechanism for preventing disuse atrophy and aiding rehabilitation beyond HMB's effects on rates of muscle protein synthesis and degradation. 12. The efficacy of HMB in combination with certain nutrients may be enhanced under select conditions.

01 Feb 2025·Journal of Cachexia, Sarcopenia and Muscle

Ergogenic Benefits of β‐Hydroxy‐β‐Methyl Butyrate (HMB) Supplementation on Body Composition and Muscle Strength: An Umbrella Review of Meta‐Analyses

Review

Author: Bideshki, Mohammad Vesal ; Behzadi, Mehrdad ; Jamilian, Parsa ; Zarezadeh, Meysam ; Jamali, Mehrdad ; Gargari, Bahram Pourghassem

ABSTRACTBackgroundβ‐Hydroxy‐β‐methyl butyrate (HMB) is a metabolite of the amino acid leucine, known for its ergogenic effects on body composition and strength. Despite these benefits, the magnitude of these effects remains unclear due to variability among studies. This umbrella review aims to synthesize meta‐analyses investigating the effects of HMB on body composition and muscle strength in adults.MethodsA comprehensive literature search was conducted in Scopus, PubMed and Web of Science without date or language restrictions until August 2024. The study protocol was registered at Prospero (No. CRD42023402740). Included studies evaluated the effects of HMB supplementation on body mass, fat mass (FM), fat‐free mass (FFM), muscle mass and performance outcomes. Effect sizes (ESs) and 95% confidence intervals (CIs) were calculated, and a random‐effects model was used for meta‐analysis. Standard methods assessed heterogeneity, sensitivity and publication bias. The methodological quality of included studies was assessed using the AMSTAR2 tool.ResultsEleven studies comprising 41 data sets were included, with participants aged 23–79 years. HMB supplementation significantly increased muscle mass (ES: 0.21; 95% CI: 0.06–0.35; p = 0.004), muscle strength index (ES: 0.27; 95% CI: 0.19–0.35; p < 0.001) and FFM (ES: 0.22; 95% CI: 0.11–0.34; p < 0.001). No significant changes were observed in FM (ES: 0.03; 95% CI: −0.04 to 0.35; p = 0.09) or body mass (ES: 0.09; 95% CI: −0.06 to 0.24; p = 0.22). The quality assessment revealed that five studies were of high quality, three were of low quality and three were of critically low quality.ConclusionsHMB supplementation may benefit individuals experiencing muscular atrophy due to physiological conditions, particularly enhancing muscle mass and strength without significant changes in fat mass or body weight.

07 Jan 2025·Diseases of the Esophagus

HMB/Arg/Gln may improve short-term outcomes after esophagectomy in patients with thoracic esophageal cancer

Article

Author: Kojima, Masatsugu ; Tani, Soichiro ; Maehira, Hiromitsu ; Takebayashi, Katsushi ; Fukuo, Asuka ; Miyake, Toru ; Tani, Masaji ; Kaida, Sachiko ; Otake, Reiko ; Mori, Haruki ; Ishikawa, Hajime

AbstractBackgroundThe wound healing effects of a specialized amino acid supplement containing calcium beta-hydroxy-beta-methylbutyrate, L-arginine, and L-glutamine (HMB/Arg/Gln) have been reported. This study aimed to investigate the effectiveness of HMB/Arg/Gln in the perioperative management of patients with thoracic esophageal cancer.MethodsThis retrospective cohort study included 131 patients who underwent esophagectomy for thoracic esophageal cancer between January 2016 and November 2023. Postoperative infectious complications (PICs) were compared between patients who received HMB/Arg/Gln for 7 days before surgery (n = 95) and those who did not (control group, n = 36).ResultsAmong the 111 male and 20 female patients (median age 68 years, range 38–84 years), stage I disease was found in 37 patients, stage II in 26, stage III in 61, and stage IVa in 7. Of the 131 patients, 36 (27.5%) had PICs, with PICs occurring in 20 (21%) of the HMB/Arg/Gln group and 16 (44.4%) of the control group. The PIC rate was significantly lower in the HMB/Arg/Gln than in the control group (p = 0.007). Propensity score matching analysis showed lower rates of anastomotic leakage (5.5% vs. 22.2%; p = 0.04) and Clavien–Dindo grade III or higher PICs (5.5% vs. 27.8%; p = 0.011) in the HMB/Arg/Gln than in the control group. The healing time for anastomotic leakage was shorter in the HMB/Arg/Gln (18 days, range 7–25 days) than in the control group (25 days, range 21–56 days) (p = 0.033).ConclusionsHMB/Arg/Gln supplementation was associated with reduced risk of anastomotic leakage and PIC severity following esophagectomy.

100 Deals associated with Beta-Hydroxy-Beta-Methylbutyrate

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Beta-Hydroxy-Beta-Methylbutyrate

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation